Search Results

Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public

On August 9, 2026, CCTV's "Morning News" program aired a feature titled "Consolidating Foundations·Sichuan: Accelerated Localization of Nuclear Medical Equipment Benefits the Public," reporting on Jiuyiyuan Company. Founded in February 2017, Sichuan Jiuyiyuan Particle Technology Co., Ltd. is a national high-tech enterprise integrating R&D, production, and services of high-end nuclear medical equipment, committed to providing overall solutions for radiopharmaceuticals. A cyclotron is a device that uses magnetic and electric fields to drive charged particles in a circular motion, repeatedly accelerating them via high-frequency electric fields during their movement. Low- and medium-energy cyclotrons applied in the medical field are devices that produce positron-emitting radionuclides, generating a variety of radionuclides that not only meet clinical PET/CT examination needs but also support the clinical positron drug and new drug development demands of the molecular imaging and precision medicine era. The report noted that core nuclear medicine equipment has long relied on imports, which is a key bottleneck constraining the development of nuclear medicine in China. In 2021, Jiuyiyuan successfully developed the first domestically produced medical cyclotron, breaking foreign technological monopoly. In June this year, the company launched the first domestically produced 30MeV multi-particle medium-to-high-energy cyclotron with fully independent intellectual property rights, with mass production planned for September, achieving internationally advanced product performance.

2026-08-10

Jiangsu's First uLinac HalosTx Integrated Ring-Gantry CT Linac Enters Clinical Use

On August 7, the first uLinac HalosTx integrated ring-gantry CT linear accelerator in Jiangsu Province was officially put into clinical use at the Third Affiliated Hospital of Nanjing Medical University (Changzhou Second People's Hospital). The system integrates a diagnostic-grade CT scanner and a ring-gantry accelerator on a single platform, shifting regional tumor radiotherapy from the traditional step-by-step positioning approach to a same-platform real-time model. Radiotherapy is one of the important modalities for cancer treatment. In the conventional split-system radiotherapy workflow, patients typically need to be transported between the CT room and the treatment room, and treatment plans are mostly formulated based on static images acquired beforehand. In cases such as tumor regression or changes in patient weight, previous images may not fully reflect the actual condition on the day of treatment...

2026-08-08

DXA Screening Among U.S. Medicare Population Declines 35% Over Nearly Two Decades

A new study shows that between 2005 and 2023, the rate of dual-energy X-ray absorptiometry (DXA) examinations among U.S. Medicare beneficiaries declined significantly, by 35%. DXA is commonly used for bone density testing and osteoporosis-related screening, and the findings suggest that disparities in screening access across different populations are widening. Researchers analyzed claims data from more than 5 million Medicare beneficiaries. The results showed that DXA utilization fell from 7,255 exams per 100,000 beneficiaries in 2005 to 4,690 per 100,000 beneficiaries in 2023. The study was published in Osteoporosis International. The decline was not uniform across populations...

2026-08-08

228 Research Reactors Worldwide in Operation, Supporting Medical Isotope Production and Neutron Science Innovation

According to the International Atomic Energy Agency on August 7, research reactors continue to drive innovation in science, medicine, and industry worldwide. Currently, 228 research reactors are in operation across 54 countries, with another 23 under construction or in the planning stage. Unlike nuclear reactors used for power generation, these reactors primarily produce neutrons to support medical, industrial, agricultural, geological, forensic, and nuclear science research. A research reactor pool photographed from above. (Photo: IAEA) In the medical field, research reactors are a vital source of medical radioisotopes. Among them, technetium-99m is widely used for diagnosing cancer and diseases of the heart, brain, and bones; a large number of medical diagnostic and therapeutic procedures worldwide rely on this isotope. Other radioisotopes such as iodine-131 are also used in the treatment of cancer and thyroid diseases. The IAEA states that radioisotopes produced by research reactors serve millions of patients globally and are an essential component of modern nuclear medicine systems.

2026-08-09

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

Thor Medical Commences Commercial Supply with First Delivery of High-Purity Thorium-228 from AlphaOne

Thor Medical ASA announced on August 5 that it has completed the first customer delivery of high-purity thorium-228 (Th-228) from its AlphaOne production facility at the Herøya industrial park. This marks the first customer shipment following the facility's production start announced last week, and signifies AlphaOne's entry into the commercial supply phase. Thor Medical CEO Jasper Kurth stated that commercial production represents the beginning of the company's industrial-scale manufacturing, and the first customer delivery demonstrates the company's transition from capacity building to serving customers through its first industrial-scale facility. The company stated that as production capacity gradually ramps up, it will continue to meet the growing demand for high-purity isotopes in the targeted alpha therapy field...

2026-08-06

South Korea advances plan to produce medical isotopes using nuclear power plants, with lutetium-177 targeted for commercial production in 2031

South Korea is advancing plans to industrialize the production of radioisotopes using nuclear power plants, with the medical isotope lutetium-177 (Lu-177) designated as the first commercial target product. Korea Hydro & Nuclear Power stated that it plans to prioritize the commercialization of Lu-177 production, with the potential to later expand the product range to include isotopes such as cobalt-60, tritium-3, and helium-3. Lu-177 is a therapeutic radioisotope widely used in the global radiopharmaceutical market, applicable in radiopharmaceuticals for diseases such as prostate cancer and neuroendocrine tumors. Previously, South Korea relied entirely on imports for its Lu-177 supply. Due to its half-life of approximately 6.6 days, the entire process from production and transportation to drug preparation and patient administration...

2026-08-06

Russia Plans to Complete Domestic MRI Scanner Development by 2027

On August 1, Russian Prime Minister Mikhail Mishustin stated that Russia should complete the development of a domestically produced MRI scanner by 2027. Mishustin learned about the relevant progress during his visit to the Consultative Diagnostic Center in the Republic of Tyva. While inspecting the MRI equipment installed at the center, he asked Russian Health Minister Mikhail Murashko about the development of domestic devices. Murashko stated that the research and development work is being carried out by Rosatom, and noted that the device is expected to be completed next year. Mishustin then expressed hope that Russia would have its own domestically developed MRI scanner next year. If the device is completed as planned, it will be used in the field of medical imaging diagnostics.

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Enzychem Lifesciences Signs MOU with Korea Institute of Radiological & Medical Sciences to Jointly Develop Radiation-Induced Dermatitis Treatment

Enzychem Lifesciences announced on August 4 that it has signed a Memorandum of Understanding (MOU) with the Korea Institute of Radiological & Medical Sciences (KIRAMS) for joint research on a treatment for radiation-induced dermatitis. Based on their respective research capabilities and expertise, the two parties will explore the feasibility of developing a treatment for radiation-induced dermatitis and advance joint new drug research. Radiation-induced dermatitis is one of the most common treatment-related side effects in cancer patients undergoing radiation therapy, manifesting as skin erythema, pain, itching, and peeling. In severe cases, it can delay or interrupt radiotherapy schedules, not only reducing patients' quality of life but also negatively affecting the treatment process. The treatment has recently...

2026-08-04

Two Joint Laboratories for Radiation Injury Treatment under the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Inaugurated in Shanghai and Wuxi

From July 30 to 31, Zhou Jiaxi, Director of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Liu Qiang, Deputy Director, Su Xu, Distinguished Professor, along with relevant heads from the National Nuclear Radiation Medical Treatment Base (Tianjin), the Science and Technology Department, and the Industry Department, successively visited Shanghai Pulmonary Hospital and the Affiliated Hospital of Jiangnan University for cooperation exchanges, and jointly inaugurated the two joint laboratories for radiation injury treatment. On the afternoon of July 30, the plaque presentation ceremony for the joint laboratory between the Institute of Radiation Medicine and Shanghai Pulmonary Hospital was held in Shanghai. Chen Chang, Deputy Secretary of the Party Committee and President of Shanghai Pulmonary Hospital, Liu Haipeng, Vice President, and heads of relevant departments attended the event. Zhou Jiaxi stated that the co-establishment of the joint laboratory is a...

2026-08-04

Zhongji Flash e-Flash 200A Enters Innovative Medical Device Special Review Program

Recently, the public notice period for the review results of applications for the Innovative Medical Device Special Review Program by the Center for Medical Device Evaluation of the National Medical Products Administration has concluded. The ultra-high dose rate electron beam radiotherapy system (e-Flash 200A), independently developed by Zhongji Flash Medical Technology Co., Ltd., has officially entered the Innovative Medical Device Special Review Program. According to reports, the e-Flash 200A is China's first ultra-high dose rate electron beam FLASH radiotherapy device and had previously been included in the "Global New" green channel. Its entry into the Innovative Medical Device Special Review Program signifies further recognition of the product's technological innovation and clinical application value. The system is designed for superficial tumor radiothe...

2026-08-04

South Korea's Deepnoid Signs M4CXR Supply Contract with Pusan National University Hospital

On August 3, Deepnoid announced the signing of a supply contract for M4CXR with Pusan National University Hospital. M4CXR is a generative AI-based preliminary report generation solution for chest X-rays that generates preliminary reports during chest X-ray examinations to assist medical staff in image interpretation. This is the first supply agreement signed after M4CXR received approval from the Ministry of Food and Drug Safety of South Korea for market release as a digital medical device. According to the introduction, the system is expected to improve the efficiency of chest X-ray reading and provide clinical support for the early detection of lung diseases and suspected cancerous lesions. This collaboration is also part of the AI clinical system support project for regional responsible medical institutions under the Ministry of Health and Welfare of South Korea...

2026-08-03